a16z Bio + Health anchors the IPO of Braveheart Bio, a heart-drug startup founded eight months ago, seeking a $1.2B valuation with no approved drugs yet.
Andreessen Horowitz, the venture capital firm that built its brand on crypto bets, is anchoring the IPO of a biotech company with zero blockchain references in its SEC filings. Braveheart Bio filed to raise up to $318.8 million in an initial public offering on Nasdaq, and a16z Bio + Health is the lead backer.
The company, founded eight months ago in November 2025, targets a valuation of up to $1.2 billion. For a firm with no approved drugs and a lead candidate still in Phase 2 trials, that is a bold ask.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on hypertrophic cardiomyopathy, or HCM. Its lead asset is BHB-1893, a cardiac myosin inhibitor in-licensed from Jiangsu Hengrui Pharmaceuticals, a major Chinese drugmaker. That licensing arrangement puts Braveheart in a crowded lane of US biotech firms sourcing compounds from China and running them through Western regulatory pathways.
Positive Phase 2 clinical data was reported in March and May 2026 for both obstructive and non-obstructive forms of HCM. Global Phase 3 trials are expected to begin in late 2026 or early 2027. The company plans to list on Nasdaq under the ticker BRVE.
Amended IPO terms as of July 30 price shares between $15 and $17, adjusting the total raise to approximately $300 million. The S-1 registration was originally filed with the SEC on July 15, 2026.
The board is chaired by Chris Viehbacher, former CEO of Biogen, with Travis Murdoch serving as CEO. Other investors alongside a16z include Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences.
Andreessen Horowitz famously raised $4.5 billion for its fourth crypto fund in 2022. When a16z starts writing large checks for biotech IPOs through its Bio + Health arm, it tells you something about the relative attractiveness of opportunities across sectors.
Braveheart's $185 million Series A funding round closed in November 2025. Eight months later, the company is going public at a potential $1.2 billion valuation. That is a roughly 6x paper markup in under a year.
Bristol Myers Squibb and Cytokinetics are both active in the HCM treatment space, which means Braveheart is entering a market with validated demand and deep-pocketed incumbents.
The China-to-US licensing model that Braveheart employs is itself a trend worth watching. As geopolitical tensions fluctuate, the regulatory pathway for compounds originating from Chinese pharmaceutical companies remains uncertain. Any policy shifts there could affect not just Braveheart but the entire cohort of US biotechs relying on similar arrangements.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.